# FXS6837 for the Treatment of IgAN Patients

> **NCT07502638** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- IgAN

## Interventions

- **DRUG:** FXS6837 Dose 1
- **DRUG:** FXS6837 Dose 2
- **DRUG:** Placebo Capsule

## Key facts

- **NCT ID:** NCT07502638
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-09-12
- **Final completion:** 2027-11-14
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502638, "FXS6837 for the Treatment of IgAN Patients". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT07502638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*